Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

as well as the Nevro1 sacroiliac joint fusion system. InvestingPro subscribers have access to 14 additional key insights about Globus Medical's growth potential and financial stability.

Globus Medical Inc. (NYSE:GMED), a medical device company with a market capitalization of $12 billion and an "GREAT" financial health rating according to InvestingPro, reaffirmed its commitment to ...

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

and the PsiFGuard device co-developed with Omnia Medical for sacroiliac fusion which recently obtained FDA clearance. The Company is also pursuing the registering process of the whole PediGuard ...